Please select the option that best describes you:
How would you approach giving concurrent chemoradiation for Stage IIIB lung adenocarcinoma in the setting of concurrent Int-2 myelofibrosis which has been stable without cytopenias on ruxolitinib?
Would you modify the radiation dose or field in this setting?
Would you pre-emptively dose reduce chemotherapy, or modify the dosing of ruxolitinib?
Answer from: Medical Oncologist at Community Practice
That is certainly a rock and a hard place. At this point, it seems as though the lung CA would be the most pressing issue. If the MF is asymptomatic (cytokine related symptoms, there are minimal spleen-related symptoms and there are no cytopenias), I would not start any treatment for the MF until th...
Sign in or Register to read more